JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia

Journal of Hematology & Oncology

Jan Cools¹  Sandrine Degryse² 

[1] Herestraat 49 (Box 602), Leuven, 3000, Belgium;KU Leuven Center for Human Genetics, Leuven, Belgium

关键词: Leukemia;    Cancer;    Mouse model;    Resistance;    Kinase inhibitor;    Targeted therapy;    Oncogenes;    Cytokine receptor;    Tyrosine kinase;   

Others  :  1221321
DOI  :  10.1186/s13045-015-0192-7

 received in 2015-02-05, accepted in 2015-07-18,  发布年份 2015

【 摘 要 】

Recent studies of acute lymphoblastic leukemia have identified activating mutations in components of the interleukin-7 receptor complex (IL7R, JAK1, and JAK3). It will be of interest to investigate both JAK1 and JAK3 kinase inhibitors as targeted agents for these leukemias.

【 授权许可】

   
2015 Degryse and Cools.

【 图 表 】

Fig. 1.

Figure 2.

【 参考文献 】

• [1]O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity. 2012; 36:542-550.
• [2]Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, Lu C, Chen S-C, Wei L, Collins-Underwood JR, Ma J, Roberts KG, Pounds SB, Ulyanov A, Becksfort J, Gupta P, Huether R, Kriwacki RW, Parker M, McGoldrick DJ, Zhao D, Alford D, Espy S, Bobba KC, Song G, Pei D et al.. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012; 481:157-163.
• [3]Zenatti PP, Ribeiro D, Li W, Zuurbier L, Silva MC, Paganin M, Tritapoe J, Hixon JA, Silveira AB, Cardoso BA, Sarmento LM, Correia N, Toribio ML, Kobarg J, Horstmann M, Pieters R, Brandalise SR, Ferrando AA, Meijerink JP, Durum SK, Yunes JA, Barata JT. Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nature Genetics. 2011; 43:932-939.
• [4]De Keersmaecker K, Atak ZK, Li N, Vicente C, Patchett S, Girardi T. Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nature Genetics. 2012;1–6.
• [5]Kalender Atak Z, Gianfelici V, Hulselmans G, De Keersmaecker K, Devasia AG, Geerdens E, Mentens N, Chiaretti S, Durinck K, Uyttebroeck A, Vandenberghe P, Wlodarska I, Cloos J, Foà R, Speleman F, Cools J, Aerts S. Comprehensive analysis of transcriptome variation uncovers known and novel driver events in T-cell acute lymphoblastic leukemia. PLoS Genet. 2013; 9: Article ID e1003997
• [6]Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L, Ariola C, Fodale V, Clappier E, Paoloni F, Martinelli S, Fragale A, Sanchez M, Tavolaro S, Messina M, Cazzaniga G, Camera A, Pizzolo G, Tornesello A, Vignetti M, Battistini A, Cave H, Gelb BD, Renauld JC, Biondi A, Constantinescu SN, Foa R, Tartaglia M. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. Journal of Experimental Medicine. 2008; 205:751-758.
• [7]Mullighana CG, Zhangb J, Harveyc RC, Collins-Underwooda JR, Schulmand BA, Phillipsa LA, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences. 2009;1–5.
• [8]Degryse S, de Bock CE, Cox L, Demeyer S, Gielen O, Mentens N, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;1–10.
• [9]Vicente C, Schwab C, Broux M, Geerdens E, Degryse S, Demeyer S: Targeted Sequencing Identifies Association Between IL7R-JAK Mutations and Epigenetic Modulators in T-Cell Acute Lymphoblastic Leukemia. Haematologica 2015: In press.
• [10]Maude SL, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A, et al. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia. Blood. 2015;1–10.
• [11]Springuel L, Hornakova T, Losdyck E, Lambert F, Leroy E, Constantinescu SN, et al. Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors. Blood. 2014;1–9.